H. Kranz

TL;DR: The practical benefit of the presented model is to identify the required shape and dimensions of drug-loaded HPMC-matrices in order to achieve desired release profiles, thus facilitating the development of new controlled drug delivery products.

TL;DR: Both, theoretical and experimental data showed that a broad spectrum of drug release patterns can be achieved by varying the size and shape of the tablet, thus significantly facilitating the development of new pharmaceutical products.

TL;DR: In vitro drug release from different in situ forming biodegradable drug delivery systems, namely polymer solutions and in situ microparticle (ISM) systems resulted in drug release profiles comparable to the drug release of microparticles prepared by the solvent evaporation method.

TL;DR: In-vivo studies confirmed the in-vitro data and showed good muscle compatibility of the ISM-systems, which resulted in significantly lower CK-levels when compared to the corresponding drug formulation in normal saline.

TL;DR: Investigation of key formulation variables affecting the release of bupivacaine hydrochloride from different in situ forming biodegradable drug delivery devices found that a slower solvent release into the aqueous medium resulted in less porous microparticles, thus explaining the reduced initial drug release from ISM systems compared to the polymer solutions.